deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT03840993

Safety and Efficacy Study of MT-2990 in Women With Endometriosis

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of MT-2990 in Women With Endometriosis Experiencing Endometrial Related Pain

Sponsor: Tanabe Pharma America, Inc.

Conditions Endometrial Related Pain
Interventions MT-2990 Placebo
Updated 16 times since 2019 Last updated: Dec 12, 2025 Started: Jan 15, 2019 Primary completion: May 13, 2021 Completion: Oct 5, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Endometrial Related Pain and is currently completed. Tanabe Pharma America, Inc. leads this study, which shows 16 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Mar 2019 – ~Oct 2019 · 7 months · monthly snapshot~Oct 2019 – ~Feb 2020 · 4 months · monthly snapshot~Feb 2020 – ~Oct 2020 · 8 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~May 2021 · 2 months · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Jan 2022 · 4 months · monthly snapshot~Jan 2022 – ~Jun 2022 · 5 months · monthly snapshot~Jun 2022 – ~May 2023 · 11 months · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Jul 2024 · 13 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Jan 2026 · 16 months · monthly snapshot~Jan 2026 – present · 6 months · monthly snapshot

Change History

16 versions recorded

  1. Jan 2026 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Jan 2026 [monthly]

    Completed PHASE2

  3. Aug 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jul 2024 — Aug 2024 [monthly]

    Completed PHASE2

  5. Jun 2023 — Jul 2024 [monthly]

    Completed PHASE2

▶ Show 11 earlier versions

  1. May 2023 — Jun 2023 [monthly]

    Completed PHASE2

  2. Jun 2022 — May 2023 [monthly]

    Completed PHASE2

  3. Jan 2022 — Jun 2022 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  4. Sep 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE2

  5. May 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

  6. Mar 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  7. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  8. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  9. Feb 2020 — Oct 2020 [monthly]

    Recruiting PHASE2

  10. Oct 2019 — Feb 2020 [monthly]

    Recruiting PHASE2

  11. Mar 2019 — Oct 2019 [monthly]

    Recruiting PHASE2

    First recorded

Jan 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Tanabe Pharma America, Inc.
Data source: Tanabe Pharma America, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Alpharetta, United States , Atlanta, United States , Bellevue, United States , Chattanooga, United States , Cleveland, United States , Columbus, United States , Covington, United States , Draper, United States , Dunwoody, United States and 32 more locations